TAKEDA PHARMACEUTIC-SP ADR (TAK) Stock Analyst Earnings Estimates
NYSE:TAK - New York Stock Exchange, Inc. - US8740602052 - ADR
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 3.569T 11.61% | 4.027T 12.85% | 4.264T 5.87% | 4.526T 6.15% | 4.565T 0.86% | 4.664T 2.16% | |
| EBITDA YoY % growth | 1.129T 26.05% | 1.215T 7.68% | 1.159T -4.65% | 1.187T 2.46% | 1.219T 2.67% | 1.268T 3.99% | |
| EBIT YoY % growth | 545.488B 62.48% | 550.895B 0.99% | 430.787B -21.80% | 228.26B -47.01% | 401.98B 76.11% | 503.99B 25.38% | |
| Operating Margin | 15.28% | 13.68% | 10.10% | 5.04% | 8.81% | 10.81% | |
| EPS YoY % growth | 74.76 -38.72% | 103.78 38.81% | 46.75 -54.95% | 39.59 -15.32% | 71.97 81.80% | 95.62 32.85% |
All data in JPY
| Q3 / 25 | Q4 / 25 | Q1 / 26 | |
|---|---|---|---|
| EPS Q2Q % growth | 10.56 -69.21% | -9.34 -815.38% | 19.95 -35.28% |
| Revenue Q2Q % growth | 1.127T 1.42% | 1.047T -0.40% | 1.134T -6.11% |
| EBITDA Q2Q % growth | 359.345B -46.47% | 158.859B -79.14% | N/A |
| EBIT Q2Q % growth | N/A | N/A | N/A |
All data in JPY
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2025 Q2Q % growth | 29.52 287.55% | 16.82 | 12.70 | 75.50% |
| Q1 2025 Q2Q % growth | 30.82 5.56% | 22.44 | 8.38 | 37.34% |
| Q4 2024 Q2Q % growth | -1.02 -110.03% | 0.40 | -1.42 | -357.78% |
| Q3 2024 Q2Q % growth | 34.31 -11.88% | 14.61 | 19.70 | 134.84% |
| Q2 2024 Q2Q % growth | -15.74 -177.99% | 18.68 | -34.42 | -184.23% |
| Q1 2024 Q2Q % growth | 29.20 -15.35% | 35.47 | -6.27 | -17.69% |
| Q4 2023 Q2Q % growth | 10.17 388.22% | 6.89 | 3.28 | 47.57% |
| Q3 2023 Q2Q % growth | 38.94 107.24% | 38.22 | 0.72 | 1.89% |
| Q2 2023 Q2Q % growth | 20.18 35.93% | 19.61 | 0.57 | 2.91% |
| Q1 2023 Q2Q % growth | 34.49 -22.76% | 36.47 | -1.98 | -5.43% |
| Q4 2022 Q2Q % growth | -3.53 -105.51% | 3.06 | -6.59 | -215.36% |
| Q3 2022 Q2Q % growth | 18.79 -37.36% | 25.93 | -7.14 | -27.54% |
| Q2 2022 Q2Q % growth | 14.85 1,229.27% | 24.25 | -9.41 | -38.79% |
| Q1 2022 Q2Q % growth | 44.66 66.19% | 34.51 | 10.15 | 29.40% |
| Q4 2021 Q2Q % growth | 64.01 11,362.22% | 24.57 | 39.44 | 160.51% |
| Q3 2021 Q2Q % growth | 30.00 886.43% | 22.25 | 7.75 | 34.83% |
| Q2 2021 Q2Q % growth | 1.12 -93.64% | 16.69 | -15.58 | -93.31% |
| Q1 2021 Q2Q % growth | 26.87 498.57% | 8.22 | 18.65 | 226.72% |
| Q4 2020 Q2Q % growth | 0.56 101.14% | -53.92 | 54.48 | 101.04% |
| Q3 2020 Q2Q % growth | 3.04 -87.44% | -15.52 | 18.56 | 119.60% |
| Q2 2020 Q2Q % growth | 17.57 -43.93% | -23.89 | 41.46 | 173.52% |
| Q1 2020 Q2Q % growth | -6.74 -113.27% | -22.31 | 15.56 | 69.77% |
| Q4 2019 Q2Q % growth | -48.93 | -40.84 | -8.09 | -19.81% |
| Q2 2019 Q2Q % growth | 31.33 | 19.28 | 12.05 | 62.53% |
| Q1 2019 Q2Q % growth | 50.79 | 35.52 | 15.27 | 42.98% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2025 Q2Q % growth | 1.176T 12.75% | 1.106T | 70.201B | 6.35% |
| Q1 2025 Q2Q % growth | 1.208T 14.11% | 1.104T | 104.296B | 9.45% |
| Q4 2024 Q2Q % growth | 1.051T 9.91% | 916.958B | 133.911B | 14.60% |
| Q3 2024 Q2Q % growth | 1.111T 1.33% | 1.017T | 93.961B | 9.24% |
| Q2 2024 Q2Q % growth | 1.043T 4.07% | 1.009T | 33.671B | 3.34% |
| Q1 2024 Q2Q % growth | 1.059T 8.86% | 992.223B | 66.395B | 6.69% |
| Q4 2023 Q2Q % growth | 956.156B 9.49% | 966.415B | -10.259B | -1.06% |
| Q3 2023 Q2Q % growth | 1.097T 21.66% | 1.015T | 81.727B | 8.05% |
| Q2 2023 Q2Q % growth | 1.002T 18.64% | 962.035B | 40.272B | 4.19% |
| Q1 2023 Q2Q % growth | 972.465B 2.41% | 934.47B | 37.995B | 4.07% |
| Q4 2022 Q2Q % growth | 873.289B 13.37% | 847.458B | 25.831B | 3.05% |
| Q3 2022 Q2Q % growth | 901.294B 7.71% | 846.517B | 54.777B | 6.47% |
| Q2 2022 Q2Q % growth | 844.82B 7.08% | 825.266B | 19.554B | 2.37% |
| Q1 2022 Q2Q % growth | 949.603B 18.43% | 873.46B | 76.143B | 8.72% |
| Q4 2021 Q2Q % growth | 770.274B -0.19% | 791.881B | -21.607B | -2.73% |
| Q3 2021 Q2Q % growth | 836.753B -2.63% | 847.525B | -10.772B | -1.27% |
| Q2 2021 Q2Q % growth | 788.935B -2.73% | 840.261B | -51.326B | -6.11% |
| Q1 2021 Q2Q % growth | 801.85B -5.57% | 814.274B | -12.424B | -1.53% |
| Q4 2020 Q2Q % growth | 771.702B 7.60% | 802.131B | -30.429B | -3.79% |
| Q3 2020 Q2Q % growth | 859.317B 72.07% | 844.174B | 15.143B | 1.79% |
| Q2 2020 Q2Q % growth | 811.048B 88.28% | 822.735B | -11.687B | -1.42% |
| Q1 2020 Q2Q % growth | 849.121B 88.76% | 824.716B | 24.405B | 2.96% |
| Q4 2019 Q2Q % growth | 717.211B | 761.028B | -43.817B | -5.76% |
| Q2 2019 Q2Q % growth | 430.777B | 475.949B | -45.172B | -9.49% |
| Q1 2019 Q2Q % growth | 449.834B | 447.597B | 2.237B | 0.50% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 0% | -14.3% | 0% | 19.55% |
| Revenue | 0% | -2.18% | 1.67% | 1.13% |